Matinas BioPharma (MTNB) Scheduled to Post Quarterly Earnings on Monday

Matinas BioPharma (NYSEAMERICAN:MTNB) will be issuing its quarterly earnings data on Monday, April 2nd.

Shares of Matinas BioPharma (NYSEAMERICAN MTNB) opened at $0.95 on Monday. The firm has a market capitalization of $96.67, a price-to-earnings ratio of -2.57 and a beta of 0.39. Matinas BioPharma has a 52-week low of $0.83 and a 52-week high of $3.20.

How to Become a New Pot Stock Millionaire

Separately, Maxim Group set a $6.00 target price on Matinas BioPharma and gave the stock a “buy” rating in a research report on Monday, March 19th.

ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3300705/matinas-biopharma-mtnb-scheduled-to-post-quarterly-earnings-on-monday.html.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Earnings History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q2 2018 Earnings Estimate for Amgen Issued By William Blair
Q2 2018 Earnings Estimate for Amgen Issued By William Blair
Restaurant Brands International to Post Q3 2018 Earnings of $0.88 Per Share, Oppenheimer Forecasts
Restaurant Brands International to Post Q3 2018 Earnings of $0.88 Per Share, Oppenheimer Forecasts
WideOpenWest  Forecasted to Post Q3 2018 Earnings of $0.21 Per Share
WideOpenWest Forecasted to Post Q3 2018 Earnings of $0.21 Per Share
Corning  Rating Increased to Buy at Zacks Investment Research
Corning Rating Increased to Buy at Zacks Investment Research
Meridian Bioscience  Issues FY18 Earnings Guidance
Meridian Bioscience Issues FY18 Earnings Guidance
Q2 2018 Earnings Forecast for Carter’s Issued By Oppenheimer
Q2 2018 Earnings Forecast for Carter’s Issued By Oppenheimer


© 2006-2018 Ticker Report. Google+.